Form DFAN14A CytoDyn Inc. Filed by: Rosenbaum Paul
- S&P 500, Dow scale new peaks; Nasdaq hit by Facebook
- Intel (INTC) Stock Plummets as Expensive Investments Expected to Pressure Margins and FCF, Prompting Three Downgrades to Neutral
- Snap (SNAP) Stock Just Crashed 25% Following Earnings, Analyst Reaction Mixed
- Beyond Meat (BYND) Stock Plunges 14% After Slashing Revenue Outlook Amid a Decrease in Retail Orders
- Dollar dips as rate hike bets fade
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ¨
Filed by a Party other than the Registrant x
Check the appropriate box:
|¨||Preliminary Proxy Statement|
|¨||Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))|
|¨||Definitive Proxy Statement|
|x||Definitive Additional Materials|
|¨||Soliciting Material Under Rule 14a-12|
(Name of Registrant as Specified in Its Charter)
PAUL A. ROSENBAUM
JEFFREY PAUL BEATY
ARTHUR L. WILMES
THOMAS J. ERRICO, M.D.
BRUCE PATTERSON, M.D.
PETER STAATS, M.D., MBA
CCTV PROXY GROUP, LLC
(Name of Persons(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|x||No fee required.|
|☐||Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.|
|(1)||Title of each class of securities to which transaction applies:|
|(2)||Aggregate number of securities to which transaction applies:|
|(3)||Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):|
|(4)||Proposed maximum aggregate value of transaction:|
|(5)||Total fee paid:|
|¨||Fee paid previously with preliminary materials:|
¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
|(1)||Amount previously paid:|
|(2)||Form, Schedule or Registration Statement No.:|
The participants named herein (collectively, the “Participants”), have filed a definitive proxy statement and accompanying WHITE proxy card with the Securities and Exchange Commission to be used to solicit votes for the election of its slate of director nominees at the 2021 annual meeting of stockholders of CytoDyn Inc., a Delaware corporation (the “Company”).
On Saturday, September 18, 2021, Jeffrey Beaty, one of the Participants, sent the following email inviting certain stockholders of the Company to attend a Zoom webinar:
You are cordially invited to attend a Zoom webinar being co-moderated by Jeff Kight and Jeff Beaty. Paul Rosenbaum, Art Wilmes, Dr. Bruce Patterson, Dr. Thomas Errico, Dr. Peter Staats, and Melissa Yeager will discuss their Long Hauler plans including trial design and financial impact for the company, proper BLA submission protocol, and potential government funding.
Please note that participation will be limited to 500 attendees and we encourage you to register in advance.
Questions should be submitted in advance to firstname.lastname@example.org.
WHEN: The webinar will be held on Tuesday, September 21, 2021 at 7:30 p.m. Eastern Daylight Time.
Register in advance for this webinar:
After registering, you will receive a confirmation email containing information about joining the webinar.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CytoDyn to Hold Webcast and Live Q/A on October 26
- Algoma Steel Receives Upgrade from S&P Global Ratings
- Laboratoires Majorelle appoints Alexandre de Germay as Chief Executive Officer
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!